Development of low-cost, shelf-stable, patient- adaptable clofazimine mini-tablets for treatment of tuberculosis in pediatrics
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93021C00042
- Awardee
-
Via Therapeutics, LLC UEI YHRZATLXKL46
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,995
Award facts
- Contract value 100% obligated
- $299,995.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Austin, TX 78750, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $299,995 |
About this award
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $299,995 firm fixed-price contract to Via Therapeutics, LLC, a small business located in Austin, Texas. The contract is for the development of low-cost, shelf-stable, patient-adaptable clofazimine mini-tablets to treat tuberculosis in pediatric patients. This contract supports Via Therapeutics' pharmaceutical research and development efforts related to infectious diseases. Via Therapeutics has received multiple past prime contracts and grants from the National Institutes of Health, including a $1.5 million contract from the National Institute of Allergy and Infectious Diseases for Phase II of a small business innovation research project to develop new tuberculosis therapeutics.
Quick answers
Who was awarded contract 75N93021C00042?
75N93021C00042 was awarded to Via Therapeutics, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 3, 2021.
How much is contract 75N93021C00042 worth?
The government has obligated $299,995 on 75N93021C00042.
Was contract 75N93021C00042 competed?
The extent of competition for 75N93021C00042 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award